Hims & Hers (HIMS) just turned a courtroom drama into a growth story and its stock has flown +40% higher today, and a little-known insulin pump maker may be quietly scripting the sequel in metabolic health.
Hims & Hers: From GLP-1 Outlaw…
GeoVax Labs (NASDAQ: GOVX) sits at the intersection of a public health problem and a balance-sheet opportunity: falling vaccination rates are quietly inflating a future bill that taxpayers, hospitals and employers will all be forced to pay. As policymakers tally the hidden…
Eupraxia Pharmaceuticals (NASDAQ: EPRX) just earned a fresh vote of confidence from Raymond James, which is doubling down on its bullish thesis and arguing that the small-cap biotech now offers one of the most attractive risk/reward setups heading into 2026. The Raymond…
French pharmaceutical group Servier has quietly become one of the most methodical players in oncology—and its latest move underscores that reputation. The company announced a definitive agreement to acquire Day One Biopharmaceuticals (Nasdaq: DAWN) for $21.50 per share in cash, valuing the…
The U.S. Food and Drug Administration (FDA) is reportedly rolling out a new cash‑bonus program to reward drug reviewers who deliver high‑quality decisions ahead of schedule, a move pitched as both a modernization of government HR and a lifeline for an agency…
Insulin pumps are having a moment, and this time it is not just Wall Street that is impressed—it is patients, payers, and, increasingly, competitors playing catch‑up.
Insulet’s Growth Streak Enters Double Digits
Insulet (PODD) closed 2025 like a company that never got…
In the end, it was not a jury but a checkbook that settled one of biotech’s more closely watched intellectual-property dramas. Moderna will pay up to 2.25 billion dollars to Genevant Sciences and Arbutus Biopharma to resolve a global web of patent…
Modular Medical’s (NASDAQ: MODD) latest capital raise seems to read less like a distress flare and more like a carefully aimed flare gun over the diabetes device market, signaling that the small-cap insurgent still plans to play big-league offense in insulin delivery…
In a conference season dominated by mega-cap immunology franchises, Eupraxia Pharmaceuticals (NASDAQ: EPRX) quietly walked into AAAAI 2026 and walked out looking a lot less “micro‑cap” and a lot more “mispriced asset.” For investors willing to do more than skim the abstracts,…
Tandem Diabetes Care’s (TNDM) latest trip to the capital markets reads less like a distress signal and more like a company quietly extending its runway in a race it fully intends to finish. At the same time, a familiar name in diabetes…